Weight loss · New Hampshire
Weight loss and obesity studies in New Hampshire
4 studies have at least one recruiting site in New Hampshire. Weight-management research includes trials of new medicines, devices, diets and lifestyle programs for people with overweight or obesity, and studies of weight-related conditions such as fatty liver disease.
4 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Lebanon, NH + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Lebanon, NH + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Portsmouth, NH + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Genetic Risk, Parental Feeding Practices, and Appetitive Traits in Early Life
Trustees of Dartmouth College
- Location
- Hanover, NH
- Eligibility basics
- Ages 2–6
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Can I join a weight loss study if I already take a GLP-1 medicine?
It depends on the study. Many exclude people currently or recently on weight-loss medicines; others are designed specifically for them. The listing’s eligibility criteria and the study team are the only reliable answer.